Matthew L. Trerotola
Net Worth

Last updated:

What is Matthew L. Trerotola net worth?

The estimated net worth of Mr. Matthew L. Trerotola is at least $173,027,189 as of 27 Sep 2025. He owns shares worth $70,479,616 as insider, has earned $68,237,573 from insider trading and has received compensation worth at least $34,310,000 in companies like Enovis Corporation, Colfax Corporation, Colfax Corporation etc.

What is the salary of Matthew L. Trerotola?

Mr. Matthew L. Trerotola salary is $2,980,000 per year as Pres, Chief Executive Officer & Director in Enovis Corporation. He also receives $2,410,000 as Pres, Chief Executive Officer & Director in Colfax Corporation and salaries from other companies.

How old is Matthew L. Trerotola?

Mr. Matthew L. Trerotola is 58 years old, born in 1967.

What stocks does Matthew L. Trerotola currently own?

As insider, Mr. Matthew L. Trerotola owns shares in 2 companies:

Company Title Shares Price per share Total value
Colfax Corporation (CFX) Pres, Chief Executive Officer & Director 413,524 $39.06 $16,152,247
Colfax Corporation (CFXA) Pres, Chief Executive Officer & Director 305,708 $177.71 $54,327,369

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.

CFX logo
CFX
Colfax Corporation
$39.06

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.

CFXA logo
CFXA
Colfax Corporation
$177.71

Matthew L. Trerotola insider trading

Colfax Corporation

Mr. Matthew L. Trerotola has made 29 insider trades between 2016-2022, according to the Form 4 filled with the SEC. Most recently he sold 12,002 units of CFX stock worth $466,638 on 7 Mar 2022.

The largest trade he's ever made was exercising 200,000 units of CFX stock on 14 May 2021. As of 27 Sep 2025 he still owns at least 413,524 units of CFX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common stock, par value $.001 12,002 $38.88 $466,638
Sale
Common stock, par value $.001 34,937 $41.18 $1,438,566
Sale
Common stock, par value $.001 6,534 $41.27 $269,658
Sale
Common stock, par value $.001 100 $41.73 $4,173
Sale
Common stock, par value $.001 57,497 $40.11 $2,306,377
Sale
Common stock, par value $.001 6,465 $41.83 $270,431
Option
Employee Stock Option (right to buy) 50,000 $39.54 $1,977,000
Sale
Common stock, par value $.001 110 $53.82 $5,920
Sale
Common stock, par value $.001 49,890 $53.02 $2,645,118
Option
Common stock, par value $.001 50,000 $39.54 $1,977,000
Option
Employee Stock Option (right to buy) 50,000 $39.54 $1,977,000
Option
Common stock, par value $.001 50,000 $39.54 $1,977,000
Sale
Common stock, par value $.001 50,000 $50.74 $2,537,200
Option
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Option
Common stock, par value $.001 59,563 $46.66 $2,779,031
Option
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Sale
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Sale
Common stock, par value $.001 59,563 $23.74 $1,414,026
Option
Employee Stock Option (right to buy) 151,446 $23.74 $3,595,328
Sale
Common stock, par value $.001 80,740 $49.37 $3,985,811
Option
Common stock, par value $.001 151,446 $49.29 $7,464,470
Option
Common stock, par value $.001 1,446 $39.54 $57,175
Option
Employee Stock Option (right to buy) 150,000 $23.74 $3,561,000
Sale
Employee Stock Option (right to buy) 70,706 $23.74 $1,678,560
Sale
Common stock, par value $.001 151,446 $31.64 $4,791,751
Sale
Employee Stock Option (right to buy) 67,951 $23.74 $1,613,157
Option
Employee Stock Option (right to buy) 150,000 $23.74 $3,561,000
Sale
Common stock, par value $.001 75,000 $23.74 $1,780,500
Option
Common stock, par value $.001 75,000 $42.89 $3,216,750
Sale
Common stock, par value $.001 7,049 $43.15 $304,136
Option
Common stock, par value $.001 200,000 $23.74 $4,748,000
Option
Employee stock option (right to buy) 200,000 $23.74 $4,748,000
Sale
Common stock, par value $.001 200,000 $23.74 $4,748,000
Sale
Common stock, par value $.001 6,057 N/A N/A
Sale
Common stock, par value $.001 22,039 N/A N/A
Sale
Common stock, par value $.001 22,039 $19.25 $424,339
Sale
Common stock, par value $.001 19,481 $30.83 $600,599
Sale
Common Stock, par value $.001 22,317 $36.84 $822,158
Sale
Common Stock, par value $.001 18,589 $28.51 $529,972
Sale
Common Stock, par value $.001 22,553 $21.36 $481,732
Sale
Common Stock, par value $.001 20,488 $33.32 $682,701
Sale
Common Stock, par value $.001 16,186 $39.76 $643,474
Sale
Common Stock, par value $.001 16,929 $36.75 $622,141
Sale
Common Stock, par value $.001 17,056 $23.6 $402,522

Colfax Corporation

Mr. Matthew L. Trerotola has made 16 insider trades in 2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 200,000 units of CFXA stock on 14 May 2021. As of 27 Sep 2025 he still owns at least 305,708 units of CFXA stock.

Transaction Date Security Shares Price per share Total value Source
Option
Employee Stock Option (right to buy) 50,000 $39.54 $1,977,000
Option
Common stock, par value $.001 50,000 $39.54 $1,977,000
Sale
Common stock, par value $.001 49,890 $53.02 $2,645,118
Sale
Common stock, par value $.001 110 $53.82 $5,920
Sale
Common stock, par value $.001 50,000 $50.74 $2,537,200
Option
Employee Stock Option (right to buy) 50,000 $39.54 $1,977,000
Option
Common stock, par value $.001 50,000 $39.54 $1,977,000
Option
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Sale
Common stock, par value $.001 59,563 $23.74 $1,414,026
Sale
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Option
Employee Stock Option (right to buy) 59,563 $23.74 $1,414,026
Option
Common stock, par value $.001 59,563 $46.66 $2,779,031
Sale
Common stock, par value $.001 151,446 $31.64 $4,791,751
Option
Common stock, par value $.001 151,446 $49.29 $7,464,470
Option
Employee Stock Option (right to buy) 150,000 $23.74 $3,561,000
Option
Common stock, par value $.001 151,446 $36.62 $5,546,558
Option
Employee Stock Option (right to buy) 151,446 $36.62 $5,546,558
Sale
Common stock, par value $.001 151,446 $49.29 $7,464,470
Sale
Common stock, par value $.001 80,740 $49.37 $3,985,811
Sale
Employee Stock Option (right to buy) 70,706 $23.74 $1,678,560
Option
Employee Stock Option (right to buy) 75,000 N/A N/A
Option
Common stock, par value $.001 75,000 N/A N/A
Sale
Common stock, par value $.001 75,000 N/A N/A
Sale
Common stock, par value $.001 75,000 $42.89 $3,216,750
Option
Employee stock option (right to buy) 75,000 $23.74 $1,780,500
Sale
Common stock, par value $.001 75,000 $23.74 $1,780,500
Option
Common stock, par value $.001 75,000 $23.74 $1,780,500
Sale
Common stock, par value $.001 200,000 N/A N/A
Option
Common stock, par value $.001 200,000 N/A N/A
Option
Employee stock option (right to buy) 200,000 N/A N/A
Sale
Common stock, par value $.001 6,057 N/A N/A
Sale
Common stock, par value $.001 22,039 N/A N/A
Sale
Common stock, par value $.001 22,039 $19.05 $419,755

Enovis key executives

Enovis Corporation executives and other stock owners filed with the SEC:

  • Mr. Bradley J. Tandy Senior Vice President, Gen. Counsel & Sec.
  • Mr. Brady R. Shirley (59) Chief Executive Officer of DJO & Executive Vice President
  • Mr. Christopher M. Hix (63) Executive Vice President of Fin. & Chief Financial Officer
  • Mr. Daniel A. Pryor (57) Executive Vice President of Strategy & Bus. Devel.
  • Mr. Matthew L. Trerotola (58) Pres, Chief Executive Officer & Director
  • Mr. Mitchell P. Rales (68) Co-Founder & Chairman
  • Mr. Shyam Kambeyanda (54) Executive Vice President and Chief Executive Officer & Pres of ESAB
  • Mr. Steven L. Breitzka Interim Senior Vice President of Global Operations & Americas
  • Mr. Terry Ross Vice President of Investor Relations, Strategy & Bus. Devel.
  • Ms. Patricia A. Lang Senior Vice President & Chief HR Officer